Annexon Bioscience Inc

Annexon Bioscience Inc. is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The company currently employs 110 individuals and generated $20.6 million in revenue. Annexon focuses on developing innovative complement medicines for patients suffering from a range of conditions. Annexon's research and development efforts center on a novel platform technology that targets the classical complement pathway, a key player in the immune system's response to disease. Their product candidates, ANX005, ANX007, and ANX009, are designed to block the activity of C1q, the initiating molecule of the classical complement pathway, potentially offering therapeutic benefits for autoimmune, neurodegenerative, and ophthalmic disorders. The company employs a rigorous, biomarker-driven strategy in its clinical trials, aiming to increase the likelihood of success for its product candidates. This data-driven approach allows Annexon to precisely monitor the effects of their treatments and optimize development strategies. For more information about Annexon Bioscience Inc. and its groundbreaking research, please visit www.annexonbio.com.